Patents by Inventor Akihiko TAGUCHI
Akihiko TAGUCHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240148895Abstract: An antibody-drug conjugate represented by formula (I): (where Ab is an antibody, X is a group represented by formula (X-1), formula (X-2) or formula (X-3): (where at the left represents the binding site with NH and at the right represents the binding side with D), D is a group represented by formula (D-1) or formula (D-2): (where represents the binding site with X), and n is in the range of about 1 to about 8).Type: ApplicationFiled: August 24, 2023Publication date: May 9, 2024Inventors: Masayuki MIYANO, Yuya NAKAZAWA, Kentaro ISO, Yuki YABE, Hirotatsu UMIHARA, Junichi TAGUCHI, Satoshi INOUE, Shuntaro TSUKAMOTO, Hiroyuki KOGAI, Atsumi YAMAGUCHI, Tsuyoshi AKAGI, Yohei MUKAI, Toshifumi HIRAYAMA, Masaki KATO, Toshiki MOCHIZUKI, Akihiko YAMAMOTO, Yuji YAMAMOTO, Takato SAKURADA
-
Patent number: 11744858Abstract: The present invention provides a sufficiently effective medicine for treatment and/or prevention of ischemic diseases, without performing isolation of therapeutic cells or removal of deleterious cells from blood cells/hemocytes. The blood cells and/or the hemocytes are subjected to the action of a saccharide. The saccharide is a monosaccharide, a disaccharide, a trisaccharide, a polysaccharides, or a copolymer containing a monosaccharide, a disaccharide, or a trisaccharide as a component. The saccharide is a copolymer of sucrose and epichlorohydrin.Type: GrantFiled: March 18, 2016Date of Patent: September 5, 2023Assignee: Foundation for Biomedical Research and Innovation at KobeInventors: Akihiko Taguchi, Kenichi Yamahara, Yukiko Niino
-
Publication number: 20230190816Abstract: The effect of physical exercise performed on a physical function of a subject with an irreversibly reduced physical function is promoted. Bone marrow mononuclear cells, CD34-positive cells, CD133-positive cells, or stem cells are contained. The central and peripheral nerves communicate intimately with each other. When these cells are administered to a subject, and the subject performs an appropriate physical exercise, the reduced physical function can be dramatically improved. The physical exercise .is, for example, physical exercise that stimulates both of brain and peripheral nerves based on the interactive biofeedback theory. Thus, for example, when bone marrow mononuclear cells are administered to a patient with a sequela of cerebral infarction, and the patient performs an appropriate physical exercise, the effect of functional recovery from the sequela of the cerebral infarction is promoted.Type: ApplicationFiled: November 26, 2020Publication date: June 22, 2023Applicant: Foundation for Biomedical Research and Innovation at KobeInventors: Akihiko TAGUCHI, Yuko OGAWA, Yuka OKINAKA, Masanori FUKUSHIMA, Atsuo YAMANAKA
-
Patent number: 11389486Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.Type: GrantFiled: July 11, 2019Date of Patent: July 19, 2022Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATIONInventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi
-
Publication number: 20220137026Abstract: The present invention relates to cells with altered cell cycle control. In particular, the present invention provides cells with altered cell cycle control and uses of such cells to identify metabolically active agents.Type: ApplicationFiled: January 13, 2022Publication date: May 5, 2022Inventors: Joseph T. Bass, Clara Bien Peek, Akihiko Taguchi, Mark Perelis, Biliana Marcheva
-
Patent number: 11255843Abstract: The present invention relates to cells with altered cell cycle control. In particular, the present invention provides cells with altered cell cycle control and uses of such cells to identify metabolically active agents.Type: GrantFiled: September 4, 2019Date of Patent: February 22, 2022Assignee: Northwestern UniversityInventors: Joseph T. Bass, Clara Bien Peek, Akihiko Taguchi, Mark Perelis, Biliana Marcheva
-
Publication number: 20210038642Abstract: The present invention provides a cell preparation in which a proportion of leukocyte in a normal form and an undesired component containing at least one selected from the group consisting of erythrocyte, deformed cell, platelet and aggregate (undesired component count/leukocyte count) is not more than a predetermined value. The aforementioned predetermined value is preferably 37.0%. In addition, the cell preparation of the present invention can be utilized for the treatment of ischemic diseases such as cerebral infarction, myocardial infarction, limb ischemia, renal infarction, pulmonary infarction, splenic infarction, the intestinal infarction, Buerger disease, cerebrovascular dementia, diabetic nephropathy microangiopathy, diabetic cardiac failure and the like.Type: ApplicationFiled: March 5, 2019Publication date: February 11, 2021Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventor: Akihiko TAGUCHI
-
Publication number: 20190391133Abstract: The present invention relates to cells with altered cell cycle control. In particular, the present invention provides cells with altered cell cycle control and uses of such cells to identify metabolically active agents.Type: ApplicationFiled: September 4, 2019Publication date: December 26, 2019Inventors: Joseph T. Bass, Clara Bien Peek, Akihiko Taguchi, Mark Perelis, Biliana Marcheva
-
Publication number: 20190388896Abstract: The mononuclear cell separation apparatus of the present invention has an injecting means (210) for injecting a centrifugation medium from the bottom surface of a container (100) storing a blood sample; a centrifugation means (300) for centrifuging a container (100) containing a centrifugation medium and a blood sample layered in this order from the bottom surface side; a detecting means (400) for detecting a clot present at a mononuclear cell layer after centrifugation; a removing means (220) for removing a detected clot; and a harvesting means (230) for harvesting the mononuclear cell. The mononuclear cell separation method of the present invention includes an injecting step, a centrifuging step, a detection step, a removing step, and a harvesting step corresponding to each constituent element of the mononuclear cell separation apparatus of the present invention.Type: ApplicationFiled: January 26, 2018Publication date: December 26, 2019Inventors: Akihiko Taguchi, Yukiko Niino, Takashi Tsumura, Kenichi Morita
-
Publication number: 20190343892Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.Type: ApplicationFiled: July 11, 2019Publication date: November 14, 2019Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATIONInventors: Kenichi YAMAHARA, Akihiko TAGUCHI, Toshihiro SOMA, Shunsuke OHNISHI, Akira KOBAYASHI
-
Patent number: 10441611Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.Type: GrantFiled: August 18, 2014Date of Patent: October 15, 2019Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATIONInventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi
-
Patent number: 10398738Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.Type: GrantFiled: August 18, 2014Date of Patent: September 3, 2019Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATIONInventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi
-
Publication number: 20180243338Abstract: The present invention provides a sufficiently effective medicine for treatment and/or prevention of ischemic diseases, without performing isolation of therapeutic cells or removal of deleterious cells from blood cells/hemocytes. The blood cells and/or the hemocytes are subjected to the action of a saccharide. The saccharide is a monosaccharide, a disaccharide, a trisaccharide, a polysaccharides, or a copolymer containing a monosaccharide, a disaccharide, or a trisaccharide as a component. The saccharide is a copolymer of sucrose and epichlorohydrin.Type: ApplicationFiled: March 18, 2016Publication date: August 30, 2018Inventors: Akihiko TAGUCHI, Kenichi YAMAHARA, Yukiko NIINO
-
Patent number: 10016409Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.Type: GrantFiled: July 14, 2017Date of Patent: July 10, 2018Assignee: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Masafumi Ihara, Takakuni Maki, Akihiko Taguchi
-
Publication number: 20180128812Abstract: The present invention relates to cells with altered cell cycle control. In particular, the present invention provides cells with altered cell cycle control and uses of such cells to identify metabolically active agents.Type: ApplicationFiled: July 18, 2017Publication date: May 10, 2018Inventors: Joseph T. Bass, Clara Bien Peek, Akihiko Taguchi, Mark Perelis, Biliana Marcheva
-
Publication number: 20170312265Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.Type: ApplicationFiled: July 14, 2017Publication date: November 2, 2017Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATIONInventors: Masafumi IHARA, Takakuni MAKI, Akihiko TAGUCHI
-
Patent number: 9737524Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.Type: GrantFiled: September 21, 2015Date of Patent: August 22, 2017Assignee: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATIONInventors: Masafumi Ihara, Takakuni Maki, Akihiko Taguchi
-
Publication number: 20160228474Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysis and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.Type: ApplicationFiled: August 18, 2014Publication date: August 11, 2016Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATIONInventors: Kenichi YAMAHARA, Akihiko TAGUCHI, Toshihiro SOMA, Shunsuke OHNISHI, Akira KOBAYASHI
-
Publication number: 20160008348Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.Type: ApplicationFiled: September 21, 2015Publication date: January 14, 2016Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATIONInventors: Masafumi IHARA, Takakuni MAKI, Akihiko TAGUCHI
-
Publication number: 20150152084Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.Type: ApplicationFiled: June 14, 2013Publication date: June 4, 2015Inventors: Masafumi Ihara, Takakuni Maki, Akihiko Taguchi